



Correction to: Ibrutinib does not prolong the corrected QT interval in healthy subjects: results from a thorough QT study

Jan de Jong¹ · Peter Hellemans² · James Juhui Jiao³ · Yuhan Huang⁴ · Sofie Mesens² · Juthamas Sukbuntherng⁵ · Daniele Ouellet⁶

Published online: 6 December 2017
© Springer-Verlag GmbH Germany, part of Springer Nature 2017

Correction to:
Cancer Chemother Pharmacol (2017) 80:1227–1237
<https://doi.org/10.1007/s00280-017-3471-x>

The author would like to correct the affiliations and conflict of interest in the publication of the original article. The corrected details are given below for your reading.

The affiliations should read as:

Jan de Jong¹, Peter Hellemans², James Juhui Jiao³, Yuhan Huang⁴, Sofie Mesens², Juthamas Sukbuntherng⁵, Daniele Ouellet⁶

¹Janssen Research and Development, LLC, San Diego, CA, USA

²Janssen Research and Development, LLC, Beerse, Belgium

³Janssen Research and Development, LLC, Raritan, NJ, USA

⁴Janssen Research and Development, LLC, Shanghai, China

⁵Pharmacyclics LLC, an AbbVie company, Sunnyvale, CA, USA

⁶Janssen Research and Development, LLC, Spring House, PA, USA

The conflict of interest section should read as:

Conflict of interest J de Jong, P Hellemans, JJ Jiao, Y Huang, S Mesens, and D Ouellet are employees of Janssen Research & Development, LLC. J Sukbuntherng is an employee of Pharmacyclics LLC, an AbbVie company.

The original article can be found online at <https://doi.org/10.1007/s00280-017-3471-x>.

✉ Jan de Jong
JDejong1@its.jnj.com

¹ Janssen Research and Development, LLC, San Diego, CA, USA

² Janssen Research and Development, LLC, Beerse, Belgium

³ Janssen Research and Development, LLC, Raritan, NJ, USA

⁴ Janssen Research and Development, LLC, Shanghai, China

⁵ Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA

⁶ Janssen Research and Development, LLC, Spring House, PA, USA